MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
Cellectar Biosciences ROCE Ratio 2011-2026 | CLRB
Annual ROCE Ratio Cellectar Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -269.17 | -362.22 | 257.01 | -353.4 | -73.03 | -27.75 | -149.55 | -86.77 | -126.44 | -69.02 | -451.81 | -86.06 | -468.7 | -81.86 | -73.96 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 257.01 | -468.7 | -161.51 |
Quarterly ROCE Ratio Cellectar Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | -61.3 | -122.59 | -159.41 | -120.68 | -135.77 | -89.55 | -66.44 | -41.57 | -48.63 | -40.62 | -33.46 | -20.79 | -62.6 | -97.34 | -124.55 | -113.85 | -136.83 | -118.01 | -105.88 | -70.32 | -102.71 | -112.11 | -120.39 | -88.43 | -106.46 | -92.1 | -79.23 | -49.68 | -160.2 | -252.69 | -356.66 | -368.19 | -399.82 | -320.93 | -235.34 | -106.28 | -233.22 | -328.53 | -411.85 | -363.98 | -383.1 | -275.27 | -177.11 | -61.34 | -80.34 | -80.22 | -82.05 | -49.89 | -19.0 | -22.41 | -8.49 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.49 | -411.85 | -143.1 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-299.89 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K |  USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Exelixis
EXEL
|
40.35 | $ 48.7 | - | $ 13.2 B | USA |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
-140.8 | $ 2.55 | - | $ 71.1 M | USA |
 |
Genmab A/S
GMAB
|
31.74 | $ 27.89 | - | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
-194.87 | $ 0.89 | - | $ 830 K | USA |
 |
Grifols, S.A.
GRFS
|
7.15 | $ 8.41 | - | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
-43.45 | $ 2.5 | - | $ 168 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-43.85 | $ 76.85 | - | $ 12.3 B | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 95.26 | - | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
-22.12 | $ 86.26 | - | $ 7.29 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-2.72 | $ 232.55 | - | $ 4.25 B | USA |
 |
INmune Bio
INMB
|
-201.42 | $ 1.52 | - | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
-114.81 | $ 42.14 | - | $ 3.63 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 21.48 | - | $ 3.56 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-7.03 | $ 110.08 | - | $ 5.53 B | USA |
 |
MannKind Corporation
MNKD
|
-76.05 | $ 3.56 | - | $ 1.09 B | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 3.15 | - | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.35 | - | $ 5.51 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
Matinas BioPharma Holdings
MTNB
|
-121.15 | $ 0.68 | - | $ 3.72 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-31.68 | $ 41.86 | - | $ 286 B | France |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.17 | - | $ 3.08 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-299.27 | - | 10.36 % | $ 9.8 M | USA |